Pharmacological Management of Obesity in Patients with Polycystic Ovary Syndrome

被引：1

作者：

Kourtidou, Christodoula ^{[1
]}

Tziomalos, Konstantinos ^{[1
]}

机构：

[1] Aristotle Univ Thessaloniki, AHEPA Hosp, Med Sch, Propedeut Dept Internal Med 1, Thessaloniki 54636, Greece

来源：

BIOMEDICINES | 2023年 / 11卷 / 02期

关键词：

polycystic ovary syndrome; obesity; overweight; glucagon-like peptide-1 receptor agonists; dipeptidyl peptidase-4 inhibitors; sodium glucose contrasporter-2 inhibitors; phosphodiesterase-4; inhibitors; RECEPTOR AGONIST LIRAGLUTIDE; TYPE-2; DIABETES-MELLITUS; SIGNIFICANT WEIGHT-LOSS; ADIPOSE-TISSUE; FAT MASS; PHOSPHODIESTERASE-4; INHIBITION; METABOLIC PARAMETERS; ENERGY-EXPENDITURE; GLYCEMIC CONTROL; WOMEN;

D O I：

10.3390/biomedicines11020496

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age. A substantial proportion of patients with PCOS are either overweight or obese, and excess body weight aggravates the hormonal, reproductive and metabolic manifestations of PCOS. In recent years, several studies evaluated the role of various pharmacological agents in the management of obesity in this population. Most reports assessed glucagon-like peptide-1 receptor agonists and showed a substantial reduction in body weight. More limited data suggest that sodium-glucose cotransporter-2 inhibitors and phosphodiesterase-4 inhibitors might also be effective in the management of obesity in these patients. In the present review, we discuss the current evidence on the safety and efficacy of these agents in overweight and obese patients with PCOS.

引用

页数：10

共 92 条

[1] Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes [J].

Abdul-Ghani, Muhammad A. ;

Norton, Luke ;

DeFronzo, Ralph A. .

ENDOCRINE REVIEWS, 2011, 32 (04) :515-531

[2] Health Effects of Overweight and Obesity in 195 Countries over 25 Years [J].

Afshin, Ashkan ;

Forouzanfar, Mohammad H. ;

Reitsma, Marissa B. ;

Sur, Patrick ;

Estep, Kara ;

Lee, Alex ;

Marczak, Laurie ;

Mokdad, Ali H. ;

Moradi-Lakeh, Maziar ;

Naghavi, Mohsen ;

Salama, Joseph S. ;

Vos, Theo ;

Abate, Kalkidan H. ;

Abbafati, Cristiana ;

Ahmed, Muktar B. ;

Al-Aly, Ziyad ;

Alkerwi, Ala'a ;

Al-Raddadi, Rajaa ;

Amare, Azmeraw T. ;

Amberbir, Alemayehu ;

Amegah, Adeladza K. ;

Amini, Erfan ;

Amrock, Stephen M. ;

Anjana, Ranjit M. ;

Arnlov, Johan ;

Asayesh, Hamid ;

Banerjee, Amitava ;

Barac, Aleksandra ;

Baye, Estifanos ;

Bennett, Derrick A. ;

Beyene, Addisu S. ;

Biadgilign, Sibhatu ;

Biryukov, Stan ;

Bjertness, Espen ;

Boneya, Dube J. ;

Campos-Nonato, Ismael ;

Carrero, Juan J. ;

Cecilio, Pedro ;

Cercy, Kelly ;

Ciobanu, Liliana G. ;

Cornaby, Leslie ;

Damtew, Solomon A. ;

Dandona, Lalit ;

Dandona, Rakhi ;

Dharmaratne, Samath D. ;

Duncan, Bruce B. ;

Eshrati, Babak ;

Esteghamati, Alireza ;

Feigin, Valery L. ;

Fernandes, Joao C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (01) :13-27

[3] Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials [J].

Alkhezi, Omar S. ;

Alahmed, Abdullah A. ;

Alfayez, Osamah M. ;

Alzuman, Osama A. ;

Almutairi, Abdulaali R. ;

Almohammed, Omar A. .

OBESITY REVIEWS, 2023, 24 (03)

[4] Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences [J].

Anagnostis, Panagiotis ;

Tarlatzis, Basil C. ;

Kauffman, Robert P. .

METABOLISM-CLINICAL AND EXPERIMENTAL, 2018, 86 :33-43

[5] Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study [J].

Astrup, Arne ;

Rossner, Stephan ;

Van Gaal, Luc ;

Rissanen, Aila ;

Niskanen, Leo ;

Al Hakim, Mazin ;

Madsen, Jesper ;

Rasmussen, Mads F. ;

Lean, Michael E. J. .

LANCET, 2009, 374 (9701) :1606-1616

[6] Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight [J].

Baggio, Laurie L. ;

Drucker, Daniel J. .

JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (10) :4223-4226

[7] GLP-1 Agonism Stimulates Brown Adipose Tissue Thermogenesis and Browning Through Hypothalamic AMPK [J].

Beiroa, Daniel ;

Imbernon, Monica ;

Gallego, Rosalia ;

Senra, Ana ;

Herranz, Daniel ;

Villarroya, Francesc ;

Serrano, Manuel ;

Ferno, Johan ;

Salvador, Javier ;

Escalada, Javier ;

Dieguez, Carlos ;

Lopez, Miguel ;

Fruehbeck, Gema ;

Nogueiras, Ruben .

DIABETES, 2014, 63 (10) :3346-3358

[8] Obesity: global epidemiology and pathogenesis [J].

Blueher, Matthias .

NATURE REVIEWS ENDOCRINOLOGY, 2019, 15 (05) :288-298

[9] Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin [J].

Bolinder, J. ;

Ljunggren, O. ;

Johansson, L. ;

Wilding, J. ;

Langkilde, A. M. ;

Sjostrom, C. D. ;

Sugg, J. ;

Parikh, S. .

DIABETES OBESITY & METABOLISM, 2014, 16 (02) :159-169

[10] Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin [J].

Bolinder, Jan ;

Ljunggren, Osten ;

Kullberg, Joel ;

Johansson, Lars ;

Wilding, John ;

Langkilde, Anna Maria ;

Sugg, Jennifer ;

Parikh, Shamik .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (03) :1020-1031

← 1 2 3 4 5 6 7 8 9 10 →